ALLISON CASSETTA: Open Payments
NPI 1467917211 · FORT COLLINS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,536 in 145 payments from 20 companies in 2025. Trend: 2023 $239 · 2024 $2,310 · 2025 $3,536
Food & beverage: $3,536
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 38 | $920 |
| Gilead Sciences, Inc. | 17 | $483 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 18 | $309 |
| Janssen Biotech, Inc. | 11 | $258 |
| Regeneron Healthcare Solutions, Inc. | 9 | $226 |
| Regeneron Pharmaceuticals, Inc. | 2 | $215 |
| Ardelyx, Inc. | 7 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $186 |
| Madrigal Pharmaceuticals | 7 | $171 |
| QOL Medical, LLC | 9 | $171 |
Products named: DUPIXENT, SKYRIZI, XIFAXAN, RINVOQ, TREMFYA, IBSRELA, REZDIFFRA, Sucraid.
Industry payments across CO — which companies pay providers there.
